Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6667314
(Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Feb, 2022
(1 year, 1 month ago) | |
US7368460 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Nov, 2022
(3 months ago) | |
US7368460
(Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
May, 2023
(2 months from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Oct 30, 2023 |
Pediatric Exclusivity (PED) | Apr 30, 2024 |
Market Authorisation Date: 04 November, 2016
Treatment: Method of treating patients infected with ccr5-tropic hiv-1
Dosage: SOLUTION;ORAL
5
United States
3
Germany
3
Malaysia
3
Spain
3
Norway
3
China
3
Hong Kong
3
European Union
2
Portugal
2
United Kingdom
2
Austria
2
Argentina
2
Korea, Republic of
2
EA
2
Japan
2
Slovenia
2
Australia
2
Denmark
1
Turkey
1
Uruguay
1
Panama
1
Guatemala
1
Brazil
1
Croatia
1
Costa Rica
1
IB
1
New Zealand
1
AP
1
Egypt
1
Estonia
1
Mexico
1
Morocco
1
Peru
1
Taiwan, Province of China
1
Tunisia
1
South Africa
1
Slovakia
1
Lithuania
1
Canada
1
Cyprus
1
ME
1
Luxembourg
1
Czech Republic
1
Iceland
1
Israel
1
Ukraine
1
OA
1
Bulgaria
1
Georgia
1
Poland
1
Yugoslavia
1
RS
1
Algeria
1
Ecuador
1
Cuba
1
Netherlands
1
Hungary
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic